Yearim, Israel

Dan Lehamann

This inventor holds 1 USPTO granted patent. Top assignee: Kabi Pharmacia Ab. Active years: 1996.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 1996

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Dan Lehamann: Innovator in Pharmaceutical Chemistry

Introduction

Dan Lehamann is a notable inventor based in Yearim, Israel. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative work on quinoline carboxamide compounds. With a focus on enhancing therapeutic efficacy, his research has implications for various medical applications.

Latest Patents

Dan Lehamann holds a patent for the "Use of substituted quinoline carboxamide." This patent represents a key advancement in the development of new pharmaceutical agents, showcasing his expertise and commitment to innovation in the industry. He has 1 patent to his name, reflecting his impactful contributions to the field.

Career Highlights

Lehamann is currently employed at Kabi Pharmacia AB, a company known for its dedication to advancing healthcare through innovative pharmaceutical solutions. His role at the company allows him to collaborate with other experts in the field and contribute to groundbreaking research.

Collaborations

Throughout his career, Dan has worked alongside esteemed colleagues such as Dimitrios Karussis and Shimon Slavin. These collaborations have fostered a rich exchange of ideas and have been instrumental in driving forward their shared goals in pharmaceutical research.

Conclusion

Dan Lehamann's work exemplifies the spirit of innovation in the pharmaceutical industry. His contributions, particularly in the area of quinoline carboxamide compounds, highlight the importance of research and collaboration in advancing healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…